| Unique ID issued by UMIN | UMIN000060576 |
|---|---|
| Receipt number | R000069286 |
| Scientific Title | A prospective study to assess the therapeutic effect of 177Lu-PSMA in patients with metastatic castration-resistant prostate cancer |
| Date of disclosure of the study information | 2026/02/04 |
| Last modified on | 2026/02/04 12:08:44 |
A prospective study to assess the therapeutic effect of 177Lu-PSMA in patients with metastatic castration-resistant prostate cancer
A prospective study to assess the therapeutic effect of 177Lu-PSMA in patients with metastatic castration-resistant prostate cancer
A prospective study to assess the therapeutic effect of 177Lu-PSMA in patients with metastatic castration-resistant prostate cancer
A prospective study to assess the therapeutic effect of 177Lu-PSMA in patients with metastatic castration-resistant prostate cancer
| Japan |
metastatic castration resistant prostate cancer
| Urology |
Malignancy
NO
To analyze the efficacy of SPECT/CT images taken after LuPSMA treatment to assess treatment efficacy.
Efficacy
Exploratory
Not applicable
radiographic progression free survival; rPFS
Overall survival from the start of LuPSMA treatment
Response assessment after completion of LuPSMA treatment (CR, PR, SD, PD)
Side effects assessment
Tumor marker changes
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
NO
NO
Institution is not considered as adjustment factor.
NO
No need to know
1
Diagnosis
| Device,equipment |
The study subjects are mCRPC patients who have undergone LuPSMA therapy. After admission to a dedicated treatment room, patients receive the prescribed dose of LuPSMA on the day of administration and are followed overnight by observation. The following day, once the dose is confirmed to be acceptable for discharge, images are taken using a SPECT/CT scan in our hospital's radioisotope (RI) laboratory to capture images of the lesion using gamma rays emitted by LuPSMA. This will be performed after the first six treatments to assess whether it is useful for assessing treatment efficacy. Conventional tumor markers and imaging tests (CT, MRI, bone scan) will be performed at standard intervals, and comparisons with these will also be conducted.
| 20 | years-old | <= |
| Not applicable |
Male
(1) Adult men aged 20 years or older
(2) Patients pathologically diagnosed with prostate cancer
(3) Patients with mCRPC undergoing LuPSMA therapy at our hospital
(4) Patients who provide written informed consent to participate in this study
(1) Patients who do not consent to this study or who refuse to participate
30
| 1st name | Yoshiyuki |
| Middle name | |
| Last name | Miyazawa |
Gunma University Hospital
Department of Urology
3718511
3-39-22 Showa-Machi, Maebashi, Gunma JAPAN
0272208306
miya.yoshi@gunma-u.ac.jp
| 1st name | Yoshiyuki |
| Middle name | |
| Last name | Miyazawa |
Gunma University Hospital
Department of Urology
3718511
3-39-22 Showa-Machi, Maebashi, Gunma JAPAN
0272208306
miya.yoshi@gunma-u.ac.jp
Gunma University
Yoshiyuki Miyazawa
Gunma University
Other
Japan
Gunma University Hospital Clinical Research Review Committee
3-39-15 Showa-Machi, Maebashi, Gunma JAPAN
027-220-8740
irb-jimukk-ciru@ml.gunma-u.ac.jp
NO
| 2026 | Year | 02 | Month | 04 | Day |
Unpublished
Open public recruiting
| 2026 | Year | 02 | Month | 04 | Day |
| 2026 | Year | 02 | Month | 04 | Day |
| 2026 | Year | 02 | Month | 04 | Day |
| 2032 | Year | 03 | Month | 31 | Day |
| 2026 | Year | 02 | Month | 04 | Day |
| 2026 | Year | 02 | Month | 04 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000069286